Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cognition Therapeutics, Inc. Market Cap
The Cognition Therapeutics, Inc. (CGTX) share price is expected to increase by 1341.86% over the next year. This is based on calculating the average 12-month share price estimate provided by 5 stock analysts who have covered CGTX. Price targets range from $1 at the low end to $11 at the high end. The current analyst consensus for CGTX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 5 Wall Street analysts have assigned CGTX 4 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Cognition Therapeutics, Inc. to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CGTX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CGTX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5 | Reiterates | Nov 27, 2024 |
Chardan Capital | Buy | Maintains | Nov 15, 2024 | |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5 | Reiterates | Nov 4, 2024 |
| Daniil Gataulin Chardan Capital | Buy | $11 | Maintains | Oct 31, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5 | Maintains | Aug 12, 2024 |
| Mayank Mamtani B. Riley Securities | Neutral | $1 | Downgrade | Aug 6, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $7 | Maintains | Aug 1, 2024 |
| Charles Duncan Cantor Fitzgerald | Neutral | Downgrade | Jul 30, 2024 | |
| Elemer Piros Rodman & Renshaw | Buy | $14 | Reiterates | Jul 2, 2024 |
| Daniil Gataulin Chardan Capital | Buy | $11 | Initiates | Jun 6, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Initiates | May 29, 2024 |
| Mayank Mamtani B. Riley Securities | Buy | $5 | Reiterates | Mar 28, 2024 |
| Jay Olson Oppenheimer | Outperform | $9 | Maintains | Mar 27, 2024 |
| Aydin Huseynov Ladenburg Thalmann | Buy | $6 | Maintains | Aug 14, 2023 |
| Jay Olson Oppenheimer | Outperform | $9 | Reiterates | May 9, 2023 |
| Jay Olson Oppenheimer | Outperform | $9 | Reiterates | Mar 24, 2023 |
| Charles Duncan Cantor Fitzgerald | Overweight | $12 | Initiates | Sep 29, 2022 |
| Aydin Huseynov Ladenburg Thalmann | Buy | $10 | Initiates | Apr 22, 2022 |
Oppenheimer | Outperform | Initiates | Nov 3, 2021 |
When did it IPO
2021
Staff Count
25
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Ms. Lisa Ricciardi
Market Cap
$16.7M
In 2023, CGTX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CGTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 28 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Cognition Therapeutics (CGTX) shows potential for a turnaround, supported by a hammer chart pattern and upward revisions in earnings estimates from Wall Street analysts.
Why It Matters - Cognition Therapeutics shows potential for recovery with a supportive chart pattern and positive analyst revisions on earnings, signaling possible upside for investors.
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CT1812 treatment led to a 95% reduction in cognitive decline in patients, with lower plasma p-tau217 levels linked to improved Alzheimer's disease indicators.
Why It Matters - The significant reduction in cognitive decline and improvement in Alzheimer's indicators with CT1812 could lead to increased demand for the treatment, positively impacting related biotech stocks.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cognition Therapeutics (NASDAQ: CGTX) announced completion of the Phase 2 SHIMMER study for CT1812 in dementia with Lewy bodies. Results are expected in December 2024.
Why It Matters - Cognition Therapeutics' upcoming results for CT1812 in December 2024 could significantly impact the company's stock price, depending on the drug's efficacy and market potential in treating dementia.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CT1812 showed a 95% reduction in cognitive decline in Alzheimer's patients with low plasma p-tau217 levels, based on Phase 2 SHINE study results presented at CTAD.
Why It Matters - The significant reduction in cognitive decline by CT1812 could indicate a breakthrough Alzheimer's treatment, potentially boosting company stock and attracting investment in biotech.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cognition Therapeutics (NASDAQ: CGTX) CEO Lisa Ricciardi will present at the Zacks SCR Life Sciences Forum on Nov 14, 2024, discussing positive Phase 2 results for CT1812 in Alzheimer's and ongoing studies.
Why It Matters - Cognition Therapeutics' presentation on promising Alzheimer’s drug results and upcoming study updates may influence investor sentiment and stock performance, indicating potential growth opportunities.
Mon, 04 Nov 2024
Sentiment - POSITIVE
Source - MarketBeat
Summary - November typically marks a profitable season for small-cap stocks, with the S&P 500 and Russell 2000 historically showing strong returns from November to April.
Why It Matters - November marks the start of a historically strong period for small-cap stocks, suggesting potential for significant returns and influencing investment strategies for the upcoming months.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
